Abstract:Thirteen amino acid substitutions have been introduced within the stretch Phe113 to Asp138 in the plasminogen activator inhibitor 1 (PAI-1) molecule by site-directed mutagenesis. The different proteins and wild-type (wt) PAI-1 have been overexpressed in Escherichia coli and purified by chromatography on heparin-Sepharose and on anhydrotrypsin-agarose. The PAI-1 variants have been characterized by their reactivity with tissue plasminogen activator (tPA), interactions with vitronectin or heparin, and stability. Most PAI-1 variants, except for Asp125-->Lys, Phe126-->Ser and Arg133-->Asp, displayed a high spontaneous inhibitory activity towards tPA, which did not change greatly on reactivation with 4 M guanidinium chloride, followed by dialysis at pH 5.5. The variants Asp125-->Lys and Arg133-->Asp became much more active after reactivation and they were also more rapidly transformed to inactive forms (t12 22-31 min) at physiological pH and temperature than the other variants. However, in the presence of vitronectin they were both almost equally stable (t12 2.3 h) as wtPAI-1 (t12 3.0 h). The mutant Glu130-->Lys showed an increased stability, both in the absence and in the presence of vitronectin compared with wtPAI-1. Nevertheless a similar affinity between all the active PAI-1 variants and vitronectin was observed. Further, all mutants, including the three mutants with low activity, were to a large extent adsorbed on anhydrotrypsin-agarose and were eluted in a similar fashion. In accordance with these data, the three variants with a low activity were all to a large extent cleaved as a result of their reaction with tPA, suggesting that they occurred predominantly in the substrate conformation. Our results do not support the presence of a binding site for vitronectin in this part of the molecule, but rather that it might be involved in controlling the active PAI-1 to substrate transition. Partly, this region of the PAI-1 molecule (Arg115 to Arg118) seems also to be involved in the binding of heparin to PAI-1.

Biological Function of Fusion Protein ATF-PAI2CD

A Hybrid Protein of the Amino-Terminal Fragment of Urokinase and Mutant Plasminogen Activator Inhibitor-2 Efficiently Inhibits Tumor Cell Invasion and Metastasis.

High-Level Expression of Active Human Plasminogen Activator Inhibitor Type 1 (Pai-1) in E-Coli

Protein Expression and Preliminary Crystallographic Analysis of Amino-Terminal Fragment of Urokinase-Type Plasminogen Activator

Renaturation, Purification, and Characterization of Human Plasminogen Activator Inhibitor Type 2 (Pai-2) Accumulated at High Level in Escherichia Coli

Expression of Human Plasminogen Activator Inhibitor-2 in the Baculovirus Expression System.

Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies

Expression of the Recombinant Plasminogen Activator (rpa) and Its Mutants

[Fusion Expression of Fibrinolytic Enzyme Gene PPFE-I from Endophytic Paenibacillus Polymyxa in Escherichia Coli and Activity Analysis].

Expression and Activity Analysis of a New Fusion Protein Targeting Ovarian Cancer Cells

Cdna Transfection of Amino-Terminal Fragment of Urokinase Efficiently Inhibits Cancer Cell Invasion and Metastasis.

Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.

Construction of Fusion Recombinant Plasmid Coding for RGD Peptide and Urokinase B Chain, Its Expression in Escherichia coil and Preliminary Characterization of Its Biological Activity

[High Level Expression of Human Atrial Natriuretic Peptide in Fusion Form in E. Coli System].

Expression of a Novel Chimeric Protein Containing the a Chain of Tissue‐type Plasminogen Activator and the B Chain of Pro‐urokinase in Insect Cells Using the Baculovirus System

[Construction of fusion recombinant plasmid coding for RGD peptide and urokinase B chain, its expression in Escherichia coli and preliminary characterization of its biological activity]

Functional Effects of Single Amino Acid Substitutions in the Region of Phe113 to Asp138 in the Plasminogen Activator Inhibitor 1 Molecule.

Expression,Purification and Crystallization of the Catalytic Domain of Inactivating Urokinase-type Plasminogen Activator in Pichia pastoris

Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1

The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.

Prokaryotic Expression of SA-hirudin-RGD Fusion Proteinand Identification of Its Anticoagulant and Anti-platelet Aggregation Function